MammoScreen

Therapixel

MammoScreen helps radiologists to identify findings on screening mammograms and assess their level of suspicion. MammoScreen™ uses the MammoScreen Score™ to provide a level-of-suspicion scoring of screenings; confirming certain findings, and pointing out unsure cases.

Product specifications

Information source: Vendor
Last updated: Jan. 7, 2021

General
Product name	MammoScreen
Company	Therapixel
Subspeciality	Breast
Modality	Mammography
Disease targeted	breast cancer
Key-features	Lesion detection and characterization, level-of-suspicion score
Suggested use	During: perception aid (prompting all abnormalities/results/heatmaps)
Data characteristics
Population	Screening mammography
Input	Screening 2D FFDM
Input format	DICOM
Output	Visual report with detected and assessed lesions
Output format	Web interface
Technology
Integration	Integration via AI marketplace or distribution platform, Stand-alone webbased
Deployment	Cloud-based
Trigger for analysis	Automatically, right after the image acquisition
Processing time	10 - 60 seconds
Certification
CE	Certified, Class IIa
FDA	510(k) cleared, Class II
Market presence
On market since	12-2020
Distribution channels	Arterys, Softway Medical, others on demand
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model	Pay-per-use
Based on	Number of analyses
Evidence
Peer reviewed papers on performance	Evaluation of Combined Artificial Intelligence and Radiologist Assessment to Interpret Screening Mammograms (read) Improving Breast Cancer Detection Accuracy of Mammography with the Concurrent Use of an Artificial Intelligence Tool (read)
Non-peer reviewed papers on performance	Breast screening and artificial intelligence: an independent evaluation of two different software carried out at Valenciennes hospital (read)
Other relevant papers